Retatrutide with MOTS-c: no study has tested the pair, and none has ever given MOTS-c to a person

What it is. Two compounds injected separately and called a metabolic stack: retatrutide, an investigational triple agonist in phase 3 for obesity, and MOTS-c, a short peptide encoded in mitochondrial DNA.

No study has tested the pair. The combination section below is empty and stays empty.

The larger problem is the second compound. MOTS-c has 277 indexed publications and a substantial human literature, and that literature measures the MOTS-c people already have in their blood. No published study has given MOTS-c to a person.

Retatrutide cannot be obtained legally either. It is investigational, approved nowhere, and material sold under the name is outside the regulated supply chain.

One structural detail is worth keeping. The two cannot be pre-blended: their storage limits after reconstitution differ, which is why even the pages selling this pairing keep them in separate vials.

No indexed study gives retatrutide and MOTS-c to the same person or animal. The combination ledger is empty.

The incumbent dosing guide that ranks second here is unusually careful about this. It states three times that no controlled trial has tested the combination, labels the schedules it prints as community-reported practice, and warns that evidence for the pairing comes from separate-compound research. Then it prints twelve tables of dosing.

This page's disagreement with it is not about the warning. It is about what follows from the warning, and about the fact that one of the two compounds has never been given to a person at all.

MOTS-c's record holds thirteen human studies. Every one of them measured circulating MOTS-c by immunoassay in people who were not given any. The peptide is endogenous: everyone has it, and its level changes with exercise, age and disease, which is what these studies report.

The studies in their own words. The 2022 breast-cancer study reported that the authors failed to find any significant alteration of circulating MOTS-c, as measured using the commercially available competitive ELISA, in response to 24 weeks of a neoadjuvant chemotherapy regimen. The 2021 exercise study in survivors found that post-exercise levels of MOTS-c among non-Hispanic White BCS were significantly associated with reductions in fat mass, body weight, HOMA-IR, CRP, and an increase in lean mass. An acute-exercise study reported that MOTS-C levels showed a trend to increase after EE. And a 2026 study of 180 people found that circulating MOTS-c levels are markedly reduced in patients with HT, Hashimoto's thyroiditis. Every verb in those sentences is about measuring.

So a compound with hundreds of papers has, in humans, the evidence base of a biomarker rather than a drug. Low MOTS-c is associated with disease; higher MOTS-c follows exercise. Neither observation says what happens when a person injects it, which is a different experiment that nobody has published.

The human dosing evidence that exists belongs to CB4211, an engineered MOTS-c analogue taken into a phase 1 trial by a company, which is not the peptide sold as MOTS-c. The dosing figures that circulate come from rodent work, where studies use milligrams per kilogram intraperitoneally, and from practitioner reports.

The same measured-not-given pattern appears on three other records here: humanin, LL-37 and kisspeptin. It is the most common way a peptide acquires a large literature without acquiring any evidence about taking it.

The rationale is clean on paper. Retatrutide reduces appetite and raises energy expenditure through three receptors; MOTS-c is associated with mitochondrial function and AMPK signalling, the machinery cells use to burn fuel. Pair a drug that creates a calorie deficit with something that helps cells handle it.

What that reasoning needs, to be more than an analogy, is evidence that injected MOTS-c does anything in a person. That evidence does not exist. The association between naturally circulating MOTS-c and better metabolic markers is real and is the reason the compound is interesting; it is not a demonstration that adding more works, any more than the association between high natural growth hormone and youth demonstrates that injecting it restores youth.

Retatrutide's own side of the pairing is well documented. Its phase 2 trial reported that at 48 weeks, the least-squares mean percentage change in the retatrutide groups was -8.7% in the 1-mg group, -17.1% in the combined 4-mg group, -22.8% in the combined 8-mg group, and -24.2% in the 12-mg group, as compared with -2.1% in the placebo group. That half of the stack is a real effect in a drug nobody can legally obtain, and the comparison pages set it out: retatrutide versus tirzepatide.

Retatrutide's published doses are the 1, 4, 8 and 12 mg weekly used in its phase 2 trial. MOTS-c's published doses are rodent doses: its record carries figures such as 5 and 15 mg/kg given intraperitoneally to mice daily, which do not translate to a person in any established way.

No dose exists for the pair, and no schedule reconciles a weekly injection with a daily rodent regimen. The two also cannot be mixed in one vial, because their stability after reconstitution differs, so the practical arrangement is two separate injections on two schedules that nobody has studied together.

Each compound's own figures sit on its record: MOTS-c and retatrutide.

Retatrutide: gastrointestinal effects dominate, worst during escalation, with dose-dependent increases in heart rate reported in its phase 2 trial. Pooled analyses of dual and triple agonists found higher discontinuation than with single-receptor drugs.

MOTS-c: nothing is known, because no person has received it in a published study. Its safety record is the absence of one, not a clean one.

For the combination there is nothing, and the usual research-chemical uncertainties apply to both halves: neither is a regulated product, and what is in either vial has not been independently verified.

Discussed for: fat loss with preserved metabolic function, by clinics and community protocols, under names like the metabolic super stack.

Studied in: for retatrutide, adults with obesity in a phase 2 trial; for MOTS-c, mice given it and people measured for it.

The unresolved questions start earlier than the combination. Whether injected MOTS-c reaches mitochondria in a person, whether it does anything measurable, and what dose would correspond to the rodent work are all open. Until the first of those is answered, a question about pairing it with anything is premature.

Retatrutide is investigational and in phase 3; there is no legal route to it outside a trial. MOTS-c is unapproved everywhere and sold as a research chemical. Neither has been assessed by a regulator, and a stack of the two is an approved product nowhere.

1. Reading MOTS-c's human literature as evidence for taking it. Every human study measured the MOTS-c people already have.
2. Quoting CB4211's trial for MOTS-c. That is an engineered analogue taken into phase 1 by a company, not the peptide sold under this name.
3. Converting rodent milligram-per-kilogram doses to human doses. Nothing published supports the conversion.
4. Treating a careful warning as a licence to print a protocol. The page ranking second here says three times that no trial tested the pair, then gives twelve tables of schedules.
5. Assuming different pathways means additive benefit. One pathway has no demonstrated human effect to add.
6. Planning around a blend. The two cannot be mixed in one vial, because their post-reconstitution stability differs.